Bacteria in dental biofilm cause 95% of the oral diseases. Lumoral® is a light-activated antibacterial solution for oral health and biofilm management, for the patient's use at home. Lumoral has been clinically proven in randomised trials to treat and prevent oral diseases.
Halitosis is caused by volatile molecules from oral or non-oral sources and is common in more than 50% of people. 90% of cases originate from oral factors like poor hygiene, gingivitis, periodontal disease, and tongue coating. It negatively affects daily life and hinders social interactions.
Halitosis can be managed with measures like thorough scaling and root planing, and enhanced oral hygiene instructions.
Lumoral eliminates odour-producing bacteria from the tooth surface and gum line while increasing the vitality of the gums.
Lumoral also helps to remove the residual plaque that usually remains on the teeth and gums after brushing. After treatment with Lumoral, you will feel smooth, slippery and clean on the surface of your teeth.
Lumoral's antimicrobial action targets the plaque bacteria that cause inflammation, but leaves normal flora unharmed. It is therefore safe to use regularly.
The use of Lumoral effectively reduces gum inflammation and regular Lumoral treatments slow down and reduce the formation of new plaque.
Control Every: 12 months
✓ Mild gingivitis
✓ Prevention of bacterial dental diseases
✓ Moderate risk for caries
✓ Moderate tartar formation
✓ Bad breath
Periodontitis treatment: patients with stable treatment results and without additional risk factors.
Control Every: 3 months
✓ High caries risk
✓ Moderate gingivitis
✓ Severe tartar formation
✓ Periodontitis stage 1-2
✓ aMMP-8 above 20 ng / ml
Periodontitis treatment: patients with additional risk factors such as diabetes mellitus, cardio-vascular disease or smoking, long-term therapy is recommended.
Control Every: 1 months
✓ Severe gingivitis
✓ Periodontitis stage 3-4
✓ aMMP-8 significantly elevated
With intensive therapy, the light activation can be increased to up to 30 minutes for every Lumorinse dose. (Longer treatment time increases the antibacterial effect).
EUROPE AND OTHER MARKET AREAS
Tero Pasanen – CCO
tero.pasanen(at)koitehealth.com
+358 40 045 9080
SOUTHERN FINLAND
Riikka Nisula – Lumoral Area Manager
riikka.nisula(at)koitehealth.com
+358 40 753 3214
CENTRAL AND NORTHERN FINLAND
Emilia Kataja – Lumoral Area Manager
emilia.kataja(at)koitehealth.com
+358 40 518 5488
STOCKHOLM AREA + SWEDEN
Helen Huttunen – Country Manager
helen.huttunen(at)koitehealth.com
+46 73 560 0092